Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-04-19
2005-04-19
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S541000, C552S544000, C552S552000
Reexamination Certificate
active
06881730
ABSTRACT:
Compounds of Formula (I) in which: R1and R2, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R3represents a methyl group having α- or β-configuration; R4represents a hydrogen atom or an etherifying or esterifying group; R5represents a hydrogen atom, a hydroxyl group or a lower alkoxy group; X represents a group OR4, wherein R4is as defined above, or a group NR6R7wherein R6represents a hydrogen atom, an aliphatic or araliphatic organic group, or an acyl group comprising an aliphatic, araliphatic or aryl organic group linked to the nitrogen atom by way of a carbonyl group; and R7is a hydrogen atom or a lower alkyl group; Y represents a lower alkylene, alkenylene or alkynylene group optionally substituted by a hydroxyl, etherified hydroxyl or esterified hydroxyl group; and the dotted lines signify that double bonds may be present at the 16(17)-position and/or either at the 6(7)- and 8(9)-positions or at the 7(8)-position exhibit potent effects on modulation of cell growth and differentiation, while having low calcaemic activity.
REFERENCES:
patent: 3562260 (1971-02-01), de Ruggieri et al.
patent: 3717627 (1973-02-01), Laing S. et al.
Dolence et al., “A stereoselective synthesis of 1,2-diols from .alpha.-hydroxyaldehydes”, Tetrahedron Letters, vol. 26(9), 1189-1192, 1985.*
Dolence et al., “A Stereoselective synthesis of 1,2-diols from alpha-hydroxyaldehydes.” Abstract from CASREACT, 1985.*
Chemical Abstracts, vol. 131, No. 8, Aug. 23, 1999, Columbus, Ohio, Abstract No. 97731, Mountford, Joanne C. et al., “Estrone potentiates myeloid cell differentiation: a role for 17.beta.-hydroxysteroid dehydrogenase in modulating hemopoiesis” XP002147254 Abstract & Exp. Hematol. (NY) 1999, 27(3), 451-460, (abstract only).
Chemical Abstracts, vol. 120, No. 23, Jun. 6, 1994, Columbus, Ohio, Abstract No. 290344, Lajeunesse, Daniel, “Effect of 17.beta.-estradiol on the human ostosarcoma cell line MG-63”, XP002147255, Abstract & Bone Miner, 1994, 24(1), 1-16, (abstract only).
Chemical Abstracts, vol. 119, No. 7,. Aug. 16, 1993, Columbus, Ohio, Abstract No. 63468, Escaleira, Maria Teresa F. et al., “Sex steroids induced up-regulation of 1,25-dihydroxyvitamin D3 receptors in T 47D breast cancer cells”, XP002147256, Abstract & J. Steroid Biochem. Mol. Biol., 1993, 45(4), 257-63, (abstract only).
Chemical Abstracts, vol. 116, No. 25, Jun. 22, 1992, Columbus, Ohio, Abstract No. 248829, Liel, Yair et al., “Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8)”, XP002147257, Abstract & Endocrinology (Baltimore), 1992, 130(5), 2597-601, (abstract only).
Hesse Robert Henry
Kugabalnsooriar Sanga
Ramgopal Malathi
Setty Sundara Katugam Srinivasasetty
Badio Barbara P.
Research Institute for Medicine & Chemistry Inc.
LandOfFree
Steroid compounds with a c17-alkyl side chain and an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Steroid compounds with a c17-alkyl side chain and an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroid compounds with a c17-alkyl side chain and an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3425270